Signos review

Signos+ has a clear purpose for someone who wants glucose feedback alongside prescription weight care: combine the medicine, an app and selected periods of sensor wear in one program. Its appeal depends on actually wanting to use that information. The included sensors are a limited allocation, so this is not continuous sensor coverage for the whole three- or six-month term. All advertised Signos+ medicines are compounded, despite the separate FDA clearance associated with its monitoring system. That distinction is central to assessing the offer. We would consider it for an eligible adult interested in structured logging and nutrition support who understands both the treatment risks and the term commitment. The website’s testimonials and internal success figures do not establish that this combination produces better long-term outcomes than another care model.

Signos provides the technology and wellness experience, while OpenLoop Health and independent licensed clinicians provide the medical care. The landing page identifies compounded semaglutide and tirzepatide as the available Signos+ treatments. Its monitoring system is described for adults who are not using insulin, and its instructions say not to make medication changes from sensor readings without consulting a qualified professional. A glucose trace can start a discussion about a meal or activity pattern; it cannot independently decide the right prescription dose. General program eligibility is ages 18 through 74, with a minimum age of 19 in Nebraska. Louisiana is excluded. Some states require a video visit during intake. Those restrictions should be resolved before treating a short online quiz as an enrollment approval.

The Signos+ help center gives a more practical account of the bundle than a broad promise of round-the-clock glucose insights. A three-month term includes two 15-day Stelo sensors; a six-month term includes four. The program recommends targeted periods of wear, such as near the beginning and end, with extra two-packs advertised at $99 for people seeking more monitoring. Compare the included wear time with how often you personally expect to use a sensor. The app supports meal and activity logging, medication tracking and wellness check-ins. Monthly check-ins help clinicians assess progress and release future medication shipments. The help article distinguishes medical support from app or account support, listing a clinical contact available seven days a week between 8 a.m. and 8 p.m. Eastern. That is a useful separation: a billing representative cannot resolve a dosing concern. Ask where nutrition support ends and clinical decision-making begins, especially when a glucose reading causes concern or symptoms do not match the device.

The starting $199 monthly figure accompanies three- or six-month programs. It should be read as a term offer until the exact payment schedule, total obligation and renewal amount are provided. Monthly medication shipments do not establish a cancel-any-month purchase. The support page says canceling renewal leaves remaining payments for the existing term due and does not create a prorated refund. The general subscription section allows app cancellation before term end, while the pharmaceutical section requires at least 72 hours before the billing date; a late request can result in another charge. Ask which instructions apply to each part of the combined order and obtain written confirmation that renewal is off. Initial medical ineligibility qualifies for a full refund, while other pharmaceutical refunds are restricted and later disqualification has its own conditions. The help center also warns that missed refill check-ins do not qualify for refunds. For a person unsure about continuing treatment, these obligations matter more than the monthly headline. Signos says it does not accept insurance. HSA or FSA reimbursement depends on the account administrator and does not override the cancellation terms.

Compounded medication is not FDA-approved, and the monitoring system’s device clearance does not extend to the drugs or prove the effectiveness of the complete Signos+ program. FDA advises that compounded drugs should be used only when an individual’s needs cannot be met by an approved medicine. Discuss that need with the prescriber and request the actual dispensing pharmacy, formulation, concentration and instructions before the first shipment. Those details are especially important when transferring from a pen or another compounded product. A glucose display also does not demonstrate that an injection contains the intended dose or establish why weight changed. Signos labels some charts as illustrative and some outcomes as internal member data; they should be read in that context. The strongest consumer case is the convenience of coordinated tools and support. Whether the sensors justify the term cost depends on their practical use, the clinician’s assessment and the patient’s willingness to complete ongoing check-ins.